1. Home
  2. FIHL vs KNSA Comparison

FIHL vs KNSA Comparison

Compare FIHL & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FIHL
  • KNSA
  • Stock Information
  • Founded
  • FIHL 2014
  • KNSA 2015
  • Country
  • FIHL Bermuda
  • KNSA United Kingdom
  • Employees
  • FIHL N/A
  • KNSA N/A
  • Industry
  • FIHL
  • KNSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • FIHL
  • KNSA Health Care
  • Exchange
  • FIHL Nasdaq
  • KNSA Nasdaq
  • Market Cap
  • FIHL 1.8B
  • KNSA 1.9B
  • IPO Year
  • FIHL 2023
  • KNSA 2018
  • Fundamental
  • Price
  • FIHL $15.94
  • KNSA $28.44
  • Analyst Decision
  • FIHL Hold
  • KNSA Strong Buy
  • Analyst Count
  • FIHL 7
  • KNSA 5
  • Target Price
  • FIHL $20.14
  • KNSA $38.80
  • AVG Volume (30 Days)
  • FIHL 786.5K
  • KNSA 707.0K
  • Earning Date
  • FIHL 08-13-2025
  • KNSA 07-22-2025
  • Dividend Yield
  • FIHL 2.51%
  • KNSA N/A
  • EPS Growth
  • FIHL N/A
  • KNSA N/A
  • EPS
  • FIHL N/A
  • KNSA N/A
  • Revenue
  • FIHL $2,558,400,000.00
  • KNSA $481,166,000.00
  • Revenue This Year
  • FIHL $24.21
  • KNSA $37.21
  • Revenue Next Year
  • FIHL $5.09
  • KNSA $5.32
  • P/E Ratio
  • FIHL N/A
  • KNSA N/A
  • Revenue Growth
  • FIHL 23.93
  • KNSA 59.45
  • 52 Week Low
  • FIHL $14.17
  • KNSA $17.38
  • 52 Week High
  • FIHL $21.32
  • KNSA $30.69
  • Technical
  • Relative Strength Index (RSI)
  • FIHL 38.01
  • KNSA 55.24
  • Support Level
  • FIHL $15.95
  • KNSA $27.62
  • Resistance Level
  • FIHL $16.99
  • KNSA $28.69
  • Average True Range (ATR)
  • FIHL 0.48
  • KNSA 1.13
  • MACD
  • FIHL -0.18
  • KNSA -0.28
  • Stochastic Oscillator
  • FIHL 1.48
  • KNSA 45.78

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Share on Social Networks: